Boston Scientific (BSX) ended the recent trading session at $44.14, demonstrating a +2.65% change from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of 0.33%. On the other hand, the Dow registered a gain of 1.08%, and the technology-centric Nasdaq increased by 0.08%.
Shares of the medical device manufacturer witnessed a loss of 2.07% over the previous month, trailing the performance of the Medical sector with its loss of 0.15%, and the S&P 500's gain of 1.41%.
The upcoming earnings release of Boston Scientific will be of great interest to investors. The company's earnings report is expected on October 28, 2026. On that day, Boston Scientific is projected to report earnings of $0.76 per share, which would represent year-over-year growth of 1.33%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.17 billion, up 2.12% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of $3.24 per share and revenue of $21.17 billion, which would represent changes of +5.88% and +5.45%, respectively, from the prior year.
Any recent changes to analyst estimates for Boston Scientific should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 1.49% lower. Currently, Boston Scientific is carrying a Zacks Rank of #4 (Sell).
In the context of valuation, Boston Scientific is at present trading with a Forward P/E ratio of 13.28. This expresses a discount compared to the average Forward P/E of 19.61 of its industry.
One should further note that BSX currently holds a PEG ratio of 1.04. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As of the close of trade yesterday, the Medical - Products industry held an average PEG ratio of 1.82.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 96, putting it in the top 40% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Boston Scientific Corporation (BSX): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).